1. Home
  2. INKT vs RNXT Comparison

INKT vs RNXT Comparison

Compare INKT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • RNXT
  • Stock Information
  • Founded
  • INKT 2017
  • RNXT 2012
  • Country
  • INKT United States
  • RNXT United States
  • Employees
  • INKT N/A
  • RNXT N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • INKT Health Care
  • RNXT Health Care
  • Exchange
  • INKT Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • INKT 36.7M
  • RNXT 31.6M
  • IPO Year
  • INKT 2021
  • RNXT 2021
  • Fundamental
  • Price
  • INKT $9.23
  • RNXT $1.03
  • Analyst Decision
  • INKT Strong Buy
  • RNXT Strong Buy
  • Analyst Count
  • INKT 2
  • RNXT 1
  • Target Price
  • INKT $6.50
  • RNXT $9.00
  • AVG Volume (30 Days)
  • INKT 73.1K
  • RNXT 207.2K
  • Earning Date
  • INKT 03-20-2025
  • RNXT 03-31-2025
  • Dividend Yield
  • INKT N/A
  • RNXT N/A
  • EPS Growth
  • INKT N/A
  • RNXT N/A
  • EPS
  • INKT N/A
  • RNXT N/A
  • Revenue
  • INKT N/A
  • RNXT N/A
  • Revenue This Year
  • INKT N/A
  • RNXT N/A
  • Revenue Next Year
  • INKT N/A
  • RNXT N/A
  • P/E Ratio
  • INKT N/A
  • RNXT N/A
  • Revenue Growth
  • INKT N/A
  • RNXT N/A
  • 52 Week Low
  • INKT $4.56
  • RNXT $0.77
  • 52 Week High
  • INKT $19.00
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • INKT 51.14
  • RNXT 31.77
  • Support Level
  • INKT $8.85
  • RNXT $1.32
  • Resistance Level
  • INKT $13.79
  • RNXT $1.18
  • Average True Range (ATR)
  • INKT 1.96
  • RNXT 0.10
  • MACD
  • INKT -0.03
  • RNXT -0.04
  • Stochastic Oscillator
  • INKT 50.60
  • RNXT 6.00

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: